Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

The antibacterial drugs market

Nature Reviews Drug Discovery volume 6, pages 19–20 (2007)Cite this article

However, the development of antibacterials has become increasingly unattractive to big pharma for a number of reasons: short antibacterial drug lifecycles; the fact that antibacterial therapy is acute, not chronic; the mature nature of the market, which is characterized by low growth and high generic penetration; and the raising of the bar for the statistical standards needed to show the efficacy of experimental drugs in clinical trials. A key factor contributing to shorter drug lifecycles is bacterial resistance. Shorter lifecycles increases the risk to drug developers (as they have less time to recoup their R&D investments); restricts sales growth (as many governments have introduced schemes to limit antibiotic use to combat resistance issues such as methicillin-resistant Staphylococcus aureus (MRSA)); and prioritizes the need for intensive lifecycle-management strategies (for example, developing an extended-release formulation).

All of these factors have led to the overriding view that big companies can spend their research dollars in more productive ways. Although the market size is significant, with an estimated total sales of US$25.5 billion in 20051, 10 out of the 15 largest companies have fully abandoned, or cut down significantly, their discovery efforts in this field since 19992. Smaller firms (such as Basilea, Theravance and Cubist) have been taking over the drug development role, both by identifying innovative drugs or formulations, and/or by picking up clinical programmes aborted by the larger companies. However, big pharma often becomes involved later through in-licensing later-stage pipeline drugs, as a strong salesforce is key to success in the community antibacterials market.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Market shares (by sales) of the leading antibacterial drug classes.
Figure 2: Growth rates of major antibacterial classes in 2001–2005.

References

  1. MIDAS Sales Data, IMS Health, September 2006.

  2. Projan, S. J. & Shlaes, D. M. Antibacterial drug discovery: is it all downhill from here? Clin. Microbiol. Infect. 10, 18–22 (2004).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hedwig Kresse and Mark Belsey are analysts at Datamonitor Healthcare, 108–110 Finchley Road, London, NW3 5JJ, UK

    Hedwig Kresse & Mark J. Belsey

  2. Holger Rovini heads the Respiratory & Infectious Disease team at Datamonitor Healthcare, 108–110 Finchley Road, London, NW3 5JJ, UK

    Holger Rovini

Authors
  1. Hedwig Kresse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark J. Belsey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Holger Rovini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Holger Rovini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kresse, H., Belsey, M. & Rovini, H. The antibacterial drugs market. Nat Rev Drug Discov 6, 19–20 (2007). https://doi.org/10.1038/nrd2226

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2226

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing